Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-02-08
DOI
10.1186/s12933-020-0991-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease
- (2019) Brian A. Ference et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2019 EXECUTIVE SUMMARY
- (2019) Alan J. Garber et al. Endocrine Practice
- Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
- (2019) Robert S. Rosenson et al. DIABETOLOGIA
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2019) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina
- (2019) Chiara Caselli et al. Cardiovascular Diabetology
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017
- (2018) Thomas R. Einarson et al. Cardiovascular Diabetology
- Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial
- (2018) Antonio J. Vallejo-Vaz et al. CIRCULATION
- Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials
- (2018) Robert R. Henry et al. DIABETES OBESITY & METABOLISM
- Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
- (2018) Kausik K. Ray et al. DIABETES OBESITY & METABOLISM
- Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
- (2018) Wieneke Dijk et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
- (2018) Stephen J. Nicholls et al. CLINICAL CARDIOLOGY
- Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials
- (2018) L. A. Leiter et al. DIABETIC MEDICINE
- Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
- (2018) Aruna D. Pradhan et al. AMERICAN HEART JOURNAL
- Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey
- (2018) Wenjun Fan et al. Journal of Clinical Lipidology
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
- (2018) Scott M. Grundy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
- (2016) Helen M. Colhoun et al. EUROPEAN HEART JOURNAL
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. EUROPEAN HEART JOURNAL
- National Lipid Association Annual Summary of Clinical Lipidology 2016
- (2016) Harold E. Bays et al. Journal of Clinical Lipidology
- Pathophysiology of diabetic dyslipidaemia: where are we?
- (2015) Bruno Vergès DIABETOLOGIA
- Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials
- (2014) George Thanassoulis et al. Journal of the American Heart Association
- Dyslipidemia
- (2013) G.B. John Mancini et al. Canadian Journal of Diabetes
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2013) EUROPEAN HEART JOURNAL
- Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials
- (2012) Jennifer G. Robinson et al. AMERICAN JOURNAL OF CARDIOLOGY
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now